101 related articles for article (PubMed ID: 33296767)
1. Peripheral cytotoxic T lymphocyte predicts first-line progression free survival in HER2-positive advanced breast cancer.
Liu XR; Yu JJ; Song GH; Di LJ; Jiang HF; Yan Y; Liang X; Zhang RY; Ran R; Wang J; Bai H; Jia SD; Li HP
Breast; 2021 Feb; 55():7-15. PubMed ID: 33296767
[TBL] [Abstract][Full Text] [Related]
2. Clinical spectrum and prognostic value of TP53 mutations in circulating tumor DNA from breast cancer patients in China.
Yi Z; Ma F; Rong G; Guan Y; Li C; Xu B
Cancer Commun (Lond); 2020 Jun; 40(6):260-269. PubMed ID: 32436611
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal HER2 amplification tracked in circulating tumor DNA for therapeutic effect monitoring and prognostic evaluation in patients with breast cancer.
Guan X; Liu B; Niu Y; Dong X; Zhu X; Li C; Li L; Yi Z; Sun X; Chen H; Lu S; Ma F
Breast; 2020 Feb; 49():261-266. PubMed ID: 31927339
[TBL] [Abstract][Full Text] [Related]
4. Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel.
Araki K; Ito Y; Fukada I; Kobayashi K; Miyagawa Y; Imamura M; Kira A; Takatsuka Y; Egawa C; Suwa H; Ohno S; Miyoshi Y
BMC Cancer; 2018 Oct; 18(1):982. PubMed ID: 30326862
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors.
Wang C; Mu Z; Ye Z; Zhang Z; Abu-Khalaf MM; Silver DP; Palazzo JP; Jagannathan G; Fellin FM; Bhattacharya S; Jaslow RJ; Tsangaris TN; Berger A; Neupane M; Cescon TP; Lopez A; Yao K; Chong W; Lu B; Myers RE; Hou L; Wei Q; Li B; Cristofanilli M; Yang H
Breast Cancer Res Treat; 2020 Jun; 181(3):679-689. PubMed ID: 32367460
[TBL] [Abstract][Full Text] [Related]
6. Identifying Circulating Tumor DNA Mutation Profiles in Metastatic Breast Cancer Patients with Multiline Resistance.
Hu ZY; Xie N; Tian C; Yang X; Liu L; Li J; Xiao H; Wu H; Lu J; Gao J; Hu X; Cao M; Shui Z; Xiao M; Tang Y; He Q; Chang L; Xia X; Yi X; Liao Q; Ouyang Q
EBioMedicine; 2018 Jun; 32():111-118. PubMed ID: 29807833
[TBL] [Abstract][Full Text] [Related]
7. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
Perez EA; de Haas SL; Eiermann W; Barrios CH; Toi M; Im YH; Conte PF; Martin M; Pienkowski T; Pivot XB; Burris HA; Stanzel S; Patre M; Ellis PA
BMC Cancer; 2019 May; 19(1):517. PubMed ID: 31146717
[TBL] [Abstract][Full Text] [Related]
8. Circulating CD8
Song Q; Ren J; Zhou X; Wang X; Song G; Hobeika A; Yuan Y; Lyerly HK
Cytotherapy; 2018 Jan; 20(1):126-133. PubMed ID: 28988693
[TBL] [Abstract][Full Text] [Related]
9. Predictive and Prognostic Role of Peripheral Blood T-Cell Subsets in Triple-Negative Breast Cancer.
Li M; Xu J; Jiang C; Zhang J; Sun T
Front Oncol; 2022; 12():842705. PubMed ID: 35242718
[TBL] [Abstract][Full Text] [Related]
10. Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER-targeted therapy in HER2 amplification-positive and HER2 mutation-positive amplification-negative patients.
Liu B; Yi Z; Guan Y; Ouyang Q; Li C; Guan X; Lv D; Li L; Zhai J; Qian H; Xu B; Ma F; Zeng Y
Cancer Med; 2022 Jul; 11(14):2767-2778. PubMed ID: 35393784
[TBL] [Abstract][Full Text] [Related]
11. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer.
Shao B; Liu X; Li H; Song G; Di L; Jiang H; Yan Y; Zhang R; Ran R; Zhang J; Liu Y; Wang H; Wang J
Curr Oncol; 2022 Aug; 29(9):6154-6166. PubMed ID: 36135052
[TBL] [Abstract][Full Text] [Related]
13. Clinical and genetic risk factors for Fulvestrant treatment in post-menopause ER-positive advanced breast cancer patients.
Liu J; Li J; Wang H; Wang Y; He Q; Xia X; Hu ZY; Ouyang Q
J Transl Med; 2019 Jan; 17(1):27. PubMed ID: 30646914
[TBL] [Abstract][Full Text] [Related]
14. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
[TBL] [Abstract][Full Text] [Related]
15. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Finn RS; Crown JP; Lang I; Boer K; Bondarenko IM; Kulyk SO; Ettl J; Patel R; Pinter T; Schmidt M; Shparyk Y; Thummala AR; Voytko NL; Fowst C; Huang X; Kim ST; Randolph S; Slamon DJ
Lancet Oncol; 2015 Jan; 16(1):25-35. PubMed ID: 25524798
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer.
Van Raemdonck E; Floris G; Berteloot P; Laenen A; Vergote I; Wildiers H; Punie K; Neven P
Breast Cancer Res Treat; 2021 Jan; 185(1):183-194. PubMed ID: 32980945
[TBL] [Abstract][Full Text] [Related]
17. Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study.
Bon G; Pizzuti L; Laquintana V; Loria R; Porru M; Marchiò C; Krasniqi E; Barba M; Maugeri-Saccà M; Gamucci T; Berardi R; Livi L; Ficorella C; Natoli C; Cortesi E; Generali D; La Verde N; Cassano A; Bria E; Moscetti L; Michelotti A; Adamo V; Zamagni C; Tonini G; Barchiesi G; Mazzotta M; Marinelli D; Tomao S; Marchetti P; Valerio MR; Mirabelli R; Russo A; Fabbri MA; D'Ostilio N; Veltri E; Corsi D; Garrone O; Paris I; Sarobba G; Giotta F; Garufi C; Cazzaniga M; Del Medico P; Roselli M; Sanguineti G; Sperduti I; Sapino A; De Maria R; Leonetti C; Di Leo A; Ciliberto G; Falcioni R; Vici P
J Exp Clin Cancer Res; 2020 Dec; 39(1):279. PubMed ID: 33302999
[TBL] [Abstract][Full Text] [Related]
18. [Value of serum human epithelial growth factor receptor 2 extracellular domain and circulating tumor cells in evaluating therapeutic response in advanced gastric cancer].
Li Y; Peng Z; Zhang X; Gong J; Shen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Nov; 20(11):1293-1299. PubMed ID: 29178102
[TBL] [Abstract][Full Text] [Related]
19. Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.
Gelmon KA; Boyle FM; Kaufman B; Huntsman DG; Manikhas A; Di Leo A; Martin M; Schwartzberg LS; Lemieux J; Aparicio S; Shepherd LE; Dent S; Ellard SL; Tonkin K; Pritchard KI; Whelan TJ; Nomikos D; Nusch A; Coleman RE; Mukai H; Tjulandin S; Khasanov R; Rizel S; Connor AP; Santillana SL; Chapman JA; Parulekar WR
J Clin Oncol; 2015 May; 33(14):1574-83. PubMed ID: 25779558
[TBL] [Abstract][Full Text] [Related]
20. Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer.
Ma F; Guan Y; Yi Z; Chang L; Li Q; Chen S; Zhu W; Guan X; Li C; Qian H; Xia X; Yang L; Zhang J; Husain H; Liao Z; Futreal A; Huang J; Yi X; Xu B
Int J Cancer; 2020 Mar; 146(5):1359-1368. PubMed ID: 31241775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
